JP2004511518A5 - - Google Patents

Download PDF

Info

Publication number
JP2004511518A5
JP2004511518A5 JP2002535660A JP2002535660A JP2004511518A5 JP 2004511518 A5 JP2004511518 A5 JP 2004511518A5 JP 2002535660 A JP2002535660 A JP 2002535660A JP 2002535660 A JP2002535660 A JP 2002535660A JP 2004511518 A5 JP2004511518 A5 JP 2004511518A5
Authority
JP
Japan
Prior art keywords
group
alkyl
alkoxy
substituted
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002535660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2001/001942 external-priority patent/WO2002032422A2/en
Publication of JP2004511518A publication Critical patent/JP2004511518A/ja
Publication of JP2004511518A5 publication Critical patent/JP2004511518A5/ja
Withdrawn legal-status Critical Current

Links

JP2002535660A 2000-10-19 2001-10-15 リウマチ様関節炎の治療のためのｅｐ４受容体インヒビター Withdrawn JP2004511518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24182500P 2000-10-19 2000-10-19
PCT/IB2001/001942 WO2002032422A2 (en) 2000-10-19 2001-10-15 Ep4 receptor inhibitors to treat rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2004511518A JP2004511518A (ja) 2004-04-15
JP2004511518A5 true JP2004511518A5 (https=) 2005-04-07

Family

ID=22912331

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002535660A Withdrawn JP2004511518A (ja) 2000-10-19 2001-10-15 リウマチ様関節炎の治療のためのｅｐ４受容体インヒビター
JP2002536282A Expired - Lifetime JP4060182B2 (ja) 2000-10-19 2001-10-15 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物
JP2007154590A Expired - Lifetime JP4703607B2 (ja) 2000-10-19 2007-06-11 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002536282A Expired - Lifetime JP4060182B2 (ja) 2000-10-19 2001-10-15 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物
JP2007154590A Expired - Lifetime JP4703607B2 (ja) 2000-10-19 2007-06-11 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物

Country Status (50)

Country Link
US (4) US20020077329A1 (https=)
EP (3) EP1326864B1 (https=)
JP (3) JP2004511518A (https=)
KR (2) KR20030048060A (https=)
CN (3) CN1477960A (https=)
AP (2) AP2003002806A0 (https=)
AR (1) AR035498A1 (https=)
AT (1) ATE320428T1 (https=)
AU (3) AU2002210796B8 (https=)
BG (2) BG107699A (https=)
BR (2) BR0114758A (https=)
CA (2) CA2426457C (https=)
CR (2) CR6951A (https=)
CY (1) CY1105035T1 (https=)
CZ (2) CZ2003979A3 (https=)
DE (1) DE60118020T2 (https=)
DK (1) DK1326864T3 (https=)
DO (1) DOP2001000271A (https=)
DZ (1) DZ3513A1 (https=)
EA (2) EA005991B1 (https=)
EC (2) ECSP034563A (https=)
EE (2) EE200300190A (https=)
ES (2) ES2258554T3 (https=)
GE (1) GEP20053673B (https=)
GT (2) GT200100211AA (https=)
HN (1) HN2001000224A (https=)
HR (1) HRP20030269A2 (https=)
HU (2) HUP0303766A3 (https=)
IL (2) IL155439A0 (https=)
IS (2) IS6765A (https=)
MA (2) MA26952A1 (https=)
MX (2) MXPA03003463A (https=)
NO (2) NO20031582L (https=)
NZ (1) NZ525163A (https=)
OA (2) OA12526A (https=)
PA (1) PA8531001A1 (https=)
PE (1) PE20020548A1 (https=)
PL (2) PL362171A1 (https=)
PT (1) PT1326864E (https=)
PY (1) PY0125983A (https=)
SI (1) SI1326864T1 (https=)
SK (2) SK4432003A3 (https=)
SV (1) SV2002000696A (https=)
TN (1) TNSN01145A1 (https=)
TW (2) TWI294424B (https=)
UA (1) UA74391C2 (https=)
UY (1) UY26977A1 (https=)
WO (2) WO2002032422A2 (https=)
YU (1) YU31303A (https=)
ZA (2) ZA200302722B (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
WO2003087061A1 (en) * 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
EP1499305A2 (en) 2002-04-12 2005-01-26 Pfizer Japan Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
WO2003086390A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003293409A1 (en) * 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1593668A4 (en) * 2003-02-14 2007-07-11 Wako Pure Chem Ind Ltd METHOD FOR PRODUCING A HYDROXYLAMINE COMPOUND USING A PLATINATE CATALYST IMMOBILIZED ON AN ION EXCHANGE RESIN
JP4185097B2 (ja) * 2003-03-13 2008-11-19 出光興産株式会社 新規含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
US20070105931A1 (en) * 2003-08-04 2007-05-10 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
EP1700129B1 (en) * 2003-12-23 2007-11-28 Roche Diagnostics GmbH Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
EP1740211A2 (en) * 2004-04-20 2007-01-10 Pfizer Products Incorporated Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
CN101084303A (zh) * 2004-11-17 2007-12-05 神经干公司 用于治疗神经变性症状的人类神经细胞的移植
AU2005316091B2 (en) * 2004-12-17 2011-12-01 Merck Canada Inc. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-D]imidazoles as mPGES-1 inhibitors
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
CN101137656B (zh) * 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
EP2019675A4 (en) * 2006-05-02 2011-03-02 Merck Frosst Canada Ltd METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US8003661B2 (en) * 2007-03-26 2011-08-23 Merck Canada Inc. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists
DE102007037579B4 (de) 2007-08-09 2012-05-16 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
MX2010002278A (es) * 2007-08-27 2010-03-17 Siga Technologies Inc Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
EP2265581A1 (en) 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
CA2737618A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
JPWO2010087425A1 (ja) 2009-01-30 2012-08-02 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
EP3431085B1 (en) * 2009-04-22 2023-10-11 AskAt Inc. Selective ep4 receptor antagonistic substance for treatment of cancer
KR101041561B1 (ko) * 2009-12-21 2011-06-15 짚라인코리아 (주) 비행용 착용복
ES2600355T3 (es) * 2010-02-22 2017-02-08 Raqualia Pharma Inc. Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis
CN103237553A (zh) 2010-07-28 2013-08-07 神经干细胞公司 治疗和/或逆转神经退行性疾病和/或病症的方法
CA2806121C (en) 2010-09-21 2018-10-09 Eisai R&D Management Co., Ltd. Pharmaceutical composition
WO2012102254A1 (ja) * 2011-01-25 2012-08-02 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩
TW201326154A (zh) * 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
CN107496421A (zh) 2013-03-19 2017-12-22 株式会社ＡｓｋＡｔ Ep4受体拮抗剂在软骨疾病的治疗中的用途
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US10059663B2 (en) * 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
JP6419857B2 (ja) 2014-03-06 2018-11-07 アラタナ セラピューティクス、 インコーポレイテッド グラピプラント組成物およびその使用方法
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
NZ733234A (en) 2014-03-06 2018-08-31 Aratana Therapeutics Inc Crystalline forms of grapiprant
MX382488B (es) 2014-10-20 2025-03-13 Neuralstem Inc Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CN105486851A (zh) * 2015-11-20 2016-04-13 中国药科大学 一种基于荧光共振能量转移技术的前列腺素受体4筛选模型
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
CN110621667A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 嘧啶衍生物
EP3625224B1 (en) 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
RU2659169C1 (ru) * 2017-10-31 2018-06-28 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования риска развития иммуноопосредованных заболеваний у работающих в условиях обсеменённости воздуха рабочей зоны условно-патогенными микроорганизмами
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
EP3820469A4 (en) * 2018-07-11 2022-04-13 Arrys Therapeutics, Inc. EP4 INHIBITORS AND SYNTHESIS THEREOF
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
JP7640458B2 (ja) 2018-10-05 2025-03-05 アンナプルナ バイオ インコーポレイテッド Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物
US11512088B2 (en) 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
WO2020160075A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
WO2021027722A1 (zh) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
US20230390303A1 (en) 2020-11-13 2023-12-07 Ono Pharmaceutical Co., Ltd. Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor
CN116478155B (zh) * 2022-01-17 2025-06-13 洛阳惠中兽药有限公司 一种格拉匹伦及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804439D0 (en) * 1988-02-25 1988-03-23 Pfizer Ltd Dihydropyridines
IL94805A (en) 1989-06-28 1994-04-12 Ciba Geigy Ag (Arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids, processfor their preparation and pharmaceutical compositions containing them
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
GB9010404D0 (en) * 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
EP1071648A2 (en) * 1998-03-13 2001-01-31 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU1444200A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for inhibiting bone resorption
EP1121133A1 (en) 1998-10-15 2001-08-08 Merck & Co., Inc. Methods for stimulating bone formation
JP2000191615A (ja) * 1998-10-20 2000-07-11 Takeda Chem Ind Ltd 芳香族アミン誘導体、その製造法および剤
EP1816127A1 (en) 1999-04-22 2007-08-08 H. Lundbeck A/S Triazine derivatives for use as selective npy (y5) antagonists
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives

Similar Documents

Publication Publication Date Title
JP2004511518A5 (https=)
EP3518975B1 (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
KR101780666B1 (ko) Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
AU2019416117A1 (en) CSF1R inhibitors for use in treating cancer
ES2565519T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de la enfermedad cardiovascular en gatos
JP2014532647A5 (https=)
KR20120089250A (ko) Ｃｋ２ 조절자로 복합 요법
EP2335731A3 (en) Multiple-variable dose regimen for treating TNF-alpha-related disorders
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2006014381A3 (en) Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies
JP2006514003A5 (https=)
CN117122707A (zh) 联合疗法
AU2016238903A1 (en) Combination of Pl3K inhibitor and c-Met inhibitor
JP2008517913A5 (https=)
RU2007124492A (ru) Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы, и их фармацевтическое применение
JP2023528722A (ja) サイトカインストーム症候群及び関連疾患を治療する方法
RU2012146874A (ru) Производные пиразолопиридина
US20060241037A1 (en) Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
JP2012516353A (ja) 血液系悪性腫瘍を治療するための方法及び組成物
JP2006514013A5 (https=)
CA2476825A1 (en) Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
US20080207644A1 (en) Therapeutic materials and methods
RU2010129038A (ru) Соединения, предназначенные для лечения рака
JP2000516257A5 (https=)